1/8 ✨Thrilled to share that our paper is now online
@NatureBiotech
“Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors”
nature.com/articles/s41587-0…
(open access): rdcu.be/fmkQp
Micropharmacology beyond Target Expression: Mapping Barriers to Intratumoral Drug Delivery—this In the Spotlight commentary by Hartland W. Jackson highlights a recent Nature Biotechnology article from Guolan Lu et al. doi.org/10.1158/0008-5472.CA…@GuolanLu
Antibody therapies show limited success in solid tumors. A new imaging technique developed at Stanford Medicine that locates antibodies at subcellular resolution in human tumors hints at why. brnw.ch/21x3P9B@GuolanLu#pharmacobiology
Thank you, Steven... we are very excited about the results because they show that, in real time, surgeons can use approaches like this to determine where and when tumors are being resected, and they might have "missed" a hidden metastasis just outside the margin of removal.
The "margin" is the safe distance into which one must cut to statistically feel confident that all the tumor is removed. In complex cancers like head and neck cancer, the tissue is so complex (tongue, veins, muscle) that it is surgically challenging not to damage nearby structures. Techniques like those Professor Guolan Lu and our colleagues developed at Stanford enable more precise surgery as well as later analysis of where a therapeutic antibody can access, or what the cancer is doing to erect barriers that block access to therapeutic drugs.
This helps us figure out what we need to do to break down such barriers.
Research from SCI members @GarryPNolan, @GuolanLu, and colleagues introduces single-cell spatial pharmacobiology, revealing how stromal barriers can limit antibody delivery and inform precision cancer therapies. brnw.ch/21x3Chr
Research from SCI members @GarryPNolan, @GuolanLu, and colleagues introduces single-cell spatial pharmacobiology, revealing how stromal barriers can limit antibody delivery and inform precision cancer therapies. brnw.ch/21x3Chr
8/8 💜 We especially thank the patients and their families for participating in the clinical trials and contributing tissue samples that made this research possible.
🏛️ We also thank our funding sources, including @theNCI, @AmericanCancer, @StanfordCancer, and @StanfordMIPS.
6/8 💡The SSP platform is broadly applicable to antibody-based therapeutics, including immune checkpoint inhibitors, antibody-drug conjugates, and multi-specific antibodies.
Incorporating SSP into early-phase clinical trials could advance the development of next-generation cancer therapeutics by uncovering mechanisms of response and resistance, guiding individualized dosing and identifying spatial biomarkers for participant stratification.
5/8 💡 These results suggest that improving antibody therapy may require not only better targets, but also strategies to overcome spatial barriers within the tumor microenvironment.
4/8 📍Using SSP in surgical window trials across tumor types, we mapped antibody distribution, target engagement, and microenvironmental barriers at single-cell resolution in intact clinical tumor tissues.
We identified a conserved stromal barrier to antibody delivery and target engagement in both head and neck cancer and pancreatic ductal adenocarcinoma.
3/8 🔬 To address this gap, we developed SSP — a new method to track:
📍 where therapeutic antibodies go
🧫 which cells they reach and engage
🧩 how the tumor microenvironment shapes their delivery and activity in situ
2/8 🎯This study was motivated by a long-standing question in cancer therapy:
Why do therapeutic antibodies fail in the majority of patients?
- Is it because therapeutic antibodies do not reach their intended targets?
- Or because they reach those targets but fail to achieve sufficient activity?
Existing methods could not directly answer this question in intact human tumors.
6/8 💡The SSP platform is broadly applicable to antibody-based therapeutics, including immune checkpoint inhibitors, antibody-drug conjugates, and multi-specific antibodies.
Incorporating SSP into early-phase clinical trials could advance the development of next-generation cancer therapeutics by uncovering mechanisms of response and resistance, guiding individualized dosing and identifying spatial biomarkers for participant stratification.
5/8 💡 These results suggest that improving antibody therapy may require not only better targets, but also strategies to overcome spatial barriers within the tumor microenvironment.
4/8 📍Using SSP in surgical window trials across tumor types, we mapped antibody distribution, target engagement, and microenvironmental barriers at single-cell resolution in intact clinical tumor tissues.
We identified a conserved stromal barrier to antibody delivery and target engagement in both head and neck cancer and pancreatic ductal adenocarcinoma.